Utilizing genomic–intensive approaches and preclinical ARDS/VILI models9–11, we previously identified extracellular nicotinamide phosphoribosyltransferase (eNAMPT) as a novel DAMP and ARDS/VILI therapeutic target and biomarker9–13. Here, NAMPT is linked to acute respiratory distress syndrome.